Indications |
Intravenous Haemorrhage Adult: Admin a test dose of 10,000 KIU at least 10 minutes before starting treatment. Loading dose: 500,000-1,000,000 KIU, given by slow inj or infusion (max rate: 100,000 KIU/minute) with the patient in supine position, may continue with 200,000 KIU/hr until the haemorrhage is controlled. Doses to be given via central venous line. Child: 1 mth-18 yr: Test dose of 200 KIU/kg, followed after 10 minutes by a dose of 10,000 KIU/kg given over 20 minutes, then continuous infusion of 3,000 KIU/kg/hr until bleeding is controlled. Intravenous Open heart surgery Adult: Admin a test dose of 10,000 KIU at least 10 minutes before starting treatment. Loading dose: 2,000,000 KIU over 20-30 minutes after induction of anaesthesia but before incision or reopening of wound, followed by continuous infusion of 500,000 KIU/hr until the end of the surgery. Add an additional dose of 2,000,000 KIU into the prime volume of the extracorporeal circuit. Doses to be given via central venous line. For patients with septic endocarditis, add a dose of 3 000 000 KIU into the prime volume of the circuit; may continue infusion into the early postoperative period. Usual total amount ≤7 000 000 KIU. Incompatibility: Incompatible with corticosteroids, heparin, tetracyclines, and nutrient solutions containing amino acids or fat emulsions. |
Contraindications |
Hypersensitivity. |
Warnings / Precautions |
Test dose should be administered to all patients at least 10 minutes before loading dose to assess for risk of hypersensitvity. Neonates and children. Greater risk of anaphylactic reactions upon re-exposure within 12 mth of previous use. Renal impairment. Pregnancy, lactation. Activated clotting time may not be a reliable method to monitor heparin therapy when on aprotinin treatment. |
Adverse Reactions |
Fever and nausea. GI disturbances. Hypersensitivity or pseudo-allergic reactions may occur after 1st dose or thereafter e.g. skin rashes and eruptions, tachycardia, pallor or cyanosis, dyspnoea and anaphylactic shock. Potentially Fatal: Fatal anaphylactic reactions. |
Drug Interactions |
May reduce hypotensive action of captopril and enalapril. Risk of apnoea when used with neuromuscular blockers. Risk of fatal thrombotic complications when used with tretinoin. See Below for More aprotinin Drug Interactions |
Lab Interactions |
Prolongs clotting time of heparinised blood. |
Mechanism of Actions |
Aprotinin is a polypeptide and inhibits proteolytic enzymes including trypsin, chymotrypsin, kallikrein and plasmin. Inhibition of plasmin inhibits fibrinolysis and reduces operative blood loss. Metabolism: Inactivated in the GI tract. Excretion: Via urine as inactive degradation products; 5-10 hr (elimination half-life). |
Storage Conditions |
Intravenous: Store at 2-25°C. |
ATC Classification |
B02AB01 - aprotinin ; Belongs to the class of proteinase inhibitor antifibrinolytics. Used in the treatment of hemorrhage. |
Storage |
Intravenous: Store at 2-25°C. |
Available As |
|
Aprotinin
Post Review about Aprotinin Click here to cancel reply.
Aprotinin Containing Brands
Aprotinin is used in following diseases
Drug - Drug Interactions of Aprotinin
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.